Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Broad genomic profiling, targeted therapy receipt, and overall survival among patients with metastatic non-squamous non-small cell lung cancer.

51 Background: Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...

Si-Da Huang, John Rothen, Jessica B. Long et al. · 0 citations
Open access Oct 2026

Cost implications of broad genomic profiling among Medicare patients with metastatic lung cancer.

37 Background: Broad genomic profiling (BGP) is increasingly used in metastatic non-small cell lung cancer (mNSCLC), but its association with downstream treatment-related Medicare spending compared to focused gene testing (FGT) remains unclear. Methods: We conducted a retrospective cohort study using SEER-Med...

Akintunde O. Aremu, Jessica B. Long, John Rothen et al. · 0 citations
Open access Oct 2026

County-level rural-urban variation in NSCLC treatment and survival among Medicare beneficiaries.

209 Background: Patients with non-small cell lung cancer (NSCLC) living in rural areas face numerous barriers to care. Although rural-urban disparities in lung cancer care are well documented, less is known about variation in treatment and survival across rural and urban counties or how these patterns have chan...

Tanvee Varma, Do Lee, P. Soulos et al. · 0 citations
Open access Oct 2026

Biomarker matched biologic use in patients with metastatic colorectal cancer (mCRC).

40 Background: The use of biologic therapy for patients with mCRC is incompletely characterized. We evaluated receipt of biomarker matched guideline concordant treatment with VEGF inhibitors (VEGFi), EGFR antibodies (EGFRa), and immune checkpoint inhibitors (ICI), assessing treatment by sociodemographic, clinic...

T. Salah, Jessica B. Long, John Rothen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.